Objectives: Interleukin-21 (IL-21) is a cytokine associated with tissue inflammation, autoimmune and infectious diseases. Organ dysfunction and death can occur in patients with acute pancreatitis (AP) in two distinct clinical phases. Initially, a systemic inflammatory response syndrome may be followed by systemic sepsis from infected pancreatic necrosis, known as the "second hit." The expression and possible role of IL-21 in AP has not been established.
I
nterleukin-21 (IL-21) is a 4-α-helical bundle cytokine predominantly produced by T H 17 cells and T follicular helper cells. 1 To a lesser extent, IL-21 is produced by natural killer (NK), CD4 + , and CD8 + T cells. 1 The IL-21 receptor (IL-21R) is a novel class I cytokine receptor mediating its effect via a common γ chain (γc). 2, 3 As a result, IL-21 has significant homology to IL-2, IL-4, IL-7, IL-9, IL-13, and IL-15. 4 The IL-21R has been recognized on a variety of cells, namely, CD4 + , CD8 + , and NK T cells; dendritic cells; and nonlymphoid tissues. 3 This implies that both the innate and adaptive immune systems may be influenced by IL-21.
A subset of proinflammatory T-helper cells, the T H 17 cells, are involved in both the innate and the adaptive immune response. 5 Developmentally distinct from the T H 1 and T H 2 responses, the T H 17 response has been demonstrated to induce potent tissue inflammation as well as being associated with multiple autoimmune and infectious diseases. 6 Additionally, T H 17 cells clear excess pathogens not adequately addressed by T H 1 or T H 2 cells. 7 Transforming growth factor β (TGF-β) and IL-6 are pivotal in the differentiation of T cells into the T H 17 subset. [8] [9] [10] However, IL-21 and TGF-β have been described as an alternative pathway for the differentiation of T H 17 cells, likely via the STAT3 signaling molecule. 11 It is believed that IL-21 has the ability to augment the T H 17 response by means of a positive feedback loop, as T H 17 cells are one of the most prominent producers of IL-21.
11,12
The relationship between IL-21 and acute pancreatitis (AP) is unknown. Acute pancreatitis is an inflammatory condition of the pancreas, as a result of various etiologies, which initiates a varied systemic inflammatory response. The majority of cases (80%-90%) are mild 13, 14 and self-limiting, with associated mortality rates of less than 1% 15, 16 in contrast to cases of severe AP (SAP) in the remainder of cases with a mortality rate of 10% to 30%. 17 Severe AP commonly has a bimodal distribution of organ dysfunction and death. Initially, a systemic inflammatory response syndrome predominates, characterized by severe, reversible multiorgan failure. [18] [19] [20] After day 7 of illness, 19,21-27 the second phase, or the so-called "second hit" of SAP, occurs as a result of septic complications arising from pancreatic necrosis. 19, 20, 28, 29 Vogelzang et al 12 demonstrated in animal models that pancreatic inflammation and exocrine damage were reduced in the absence of IL-21/IL-21R signaling, suggesting that IL-21 may exacerbate pancreatic inflammation and therefore pancreatitis. To date, there is no literature as to whether IL-21 influences the septic outcomes that occur in patients with SAP; hence, this study aimed to determine the expression of IL-21 in the second hit of pancreatitis. In addition, the relationship between local complications (necrosis and sepsis) relative to IL-21 production was investigated.
MATERIALS AND METHODS

Sampling and Clinical Parameters
Ethical approval was obtained from the Human Research Ethics Committee of the University of the Witwatersrand, Johannesburg (clearance no. M160254). Thirty-six patients diagnosed with AP, according to the revised Atlanta Classification, 30 were enrolled. Only patients presenting prior to day 7 of onset of symptoms were considered for inclusion. Patients with severe comorbidities, chronic inflammatory conditions, and malignancy were excluded. Although moderately severe AP is classified as a discreet subgroup, it is associated with a mortality rate of 2%, 31 similar to mild AP of less than 1%, 15, 16 and hence patients with mild and moderate AP (MAP) were combined into 1 group and compared with SAP patients.
Six healthy participants were recruited as control subjects. Sample collection took place at the tertiary care Chris Hani Baragwanath Academic Hospital in Soweto, Johannesburg, as well as the Wits Donald Gordon Medical Centre in Johannesburg between June 2016 and July 2017. Peripheral blood samples were drawn in EDTA tubes on days 7, 9, 11, and 13 of illness and processed within 3 hours of collection. Plasma was aspirated from the rested sample and centrifuged at 2200 revolutions per minute (1800g) for 10 minutes prior to being stored at −80°C. To prevent damage of the biomolecules of the samples, freeze thawing was avoided, and only single-use sample aliquots were prepared and used for the bioassays.
Where the diagnosis of AP was in doubt or where patients were suspected to have developed local complications, abdominal computed tomography scans were obtained. The revised Atlanta Classification was used to define local complications, including necrosis. 30 Either a positive blood culture or retroperitoneal air associated with a collection requiring drainage was used in this study to define sepsis. Clinical management decisions were not influenced by the study protocol. Admitting clinicians were not influenced by the study's researchers.
Sample Size
The detection of a medium effect size (f = 0.25) with 80% power at the 5% significance level, assuming a 0.5 correlation between the 4 repeated measures, required a total sample size of 82 (41 per group). The actual sample size of 36 in this study was adequate only for the detection of large effect sizes ( f = 0.38).
IL-21 Quantification by Enzyme-Linked Immunosorbent Assay
An enzyme-linked immunosorbent assay (ELISA) was performed using the Invitrogen Human IL-21 kit (Thermo Fisher Scientific, Waltham, Mass) as per manufacturer's instructions on all 36 patient samples as well as all control subjects. The IL-21 concentration was determined from a curve of absorbance (570-450 nm) against known standard concentrations. Absorbance was determined using a Thermo Fisher Scientific Multiskan GO Spectrophotometer plate reader. The kit has a documented detection range of 8 to 1000 pg/mL.
Between-group comparisons of the repeated-measures continuous clinical and study variables were performed. A repeatedmeasures mixed model with an AR (1) covariance matrix, with post hoc comparisons (Tukey Kramer adjustment for multiple comparisons) between days (within groups) and between groups (within days), was performed to allow for any missing data. A natural log transformation of the dependent variable was carried out where necessary, to meet the assumptions of the analysis technique. Where such variables contained values of zero, an amount equal to one half of the next smallest value was added to all values before performing the transformation. The results were then back-transformed to estimated means. Data analysis was carried out in SAS (Statistical Analysis System, Cary, NC) version 9.4 for Windows. The 5% significance level was used.
Total RNA Extraction and Quantification for IL-21 mRNA
Total RNA was extracted using TRI Reagent BD (Sigma T3809, St Louis, Mo). A total of 10 randomly selected patient plasma samples (5 mild AP, 5 SAP and 4 control samples) were used. Frozen plasma samples were brought to room temperature. Two hundred microliters of the plasma was transferred to a sterile Eppendorf tube containing 750 μL of TRI Reagent BD and 20 μL of 5 N acetic acid. The mixture was left to incubate for 5 minutes at 25°C and followed by the addition of 200 μL of chloroform. The mixture was thoroughly shaken for about 20 seconds and allowed to incubate at 25°C for 3 minutes. Subsequently, the mixture was centrifuged at 12,000g for 15 minutes at 4°C to separate into 3 phases. The aqueous phase was carefully transferred to a fresh Eppendorf tube and 500 μL of isopropanol added. This mixture was further centrifuged at 13,000g for 10 minutes at 4°C to pellet RNA. The supernatant was discarded, 1 mL of 75% ethanol added to the RNA pellet, and centrifuged at 7500g for 5 minutes at 25°C. The ethanol layer was discarded, and the RNA pellet allowed to air dry for 10 minutes after which 50 μL of RNase-Free water (Qiagen, Venlo, Netherlands) was added. Samples were quantified using the Nanodrop 1000 (Thermo Fisher Scientific). All total RNA samples were observed to have an A260/280 ratio greater than 1.8.
Reverse Transcriptase-Polymerase Chain Reaction
Complementary DNA was generated using the First Strand cDNA Synthesis Kit (New England BioLabs E6300, Ipswich, Mass). An amount of 1 μg total RNA was used from each sample, and cDNA synthesis performed according to the manufacturer's protocol. Reverse transcriptase-polymerase chain reaction was performed using the New England Biolabs' OneTaq 2X Master Mix with Standard Buffer (M0482) and cycling conditions set as per manufacturer's instructions. Primers used for the study were as follows:
IL-21 Fwd: 5′-GTCATCTGTCTGATGGTCATCTTCTT-3′ Rev: 5′-TCAGGGACCAAGTCATTCACATA-3′ and RPL 13A Fwd: 5′-CATAGGAAGCTGGGAGCAAG-3′ Rev: 5′-GCCCTCCAATCAGTCTTCTG-3′.
Agarose Gel Electrophoresis
Polymerase chain reaction samples (12 μL) were mixed with 6Â loading dye (Sigma G7654). The mixture was run on a 2% agarose gel at 70 V for 45 minutes and image viewed using a Bio-Rad Gel Doc system (Bio-Rad, Hercules, Calif ).
Image and Statistical Analysis
The MyImage analysis software version 4.0 (Thermo Fisher Scientific) was used for band quantification. Mean and standard deviation (SD) were calculated from optical densities of bands in Microsoft Excel 2013 (Microsoft Corporation, Redmond, Wash). P < 0.05 was considered statistically significant.
RESULTS
Patient Information
Thirty-six patients and 6 healthy control subjects were enrolled into the study. Patients were between 22 and 78 years of age. Twenty-six patients had MAP, and 10 patients had SAP. Necrosis developed in 3 (12%) of the patients with MAP and 5 (50%) in the severe group. Four (40%) of the patients in the severe group developed septic complications, with none occurring in the mild/moderate group.
Five samples each of patients with mild and SAP, respectively, were randomly selected for analysis of IL-21 mRNA expression as well as 4 control subjects. Of these 10, 4 of the SAP patients developed local complications. Necrosis and sepsis occurred in 3 of these SAP patients.
IL-21 Production Measured by ELISA
When all 36 patient samples were analyzed, a moderate increase in IL-21 concentration was observed on days 9, 11, and 13 in SAP compared with MAP patients, which was not statistically significant (Fig. 1A) . No differences were noted between the IL-21 levels in the patients and the control subjects, although patient levels tended to be lower than the control subjects over all study days (Fig. 1A) . Furthermore, no significant differences were noted in variations of IL-21 levels over the study period with each of the groups.
Subgroup analysis of ELISA data for the 10 randomly selected samples used in the mRNA assay is represented in Fig. 1B to allow for comparison of the IL-21 patterns between the 2 assays (Figs. 1B and 2 ). In the SAP patients, IL-21 was higher than that in the mild AP patients throughout the study period; however, this was not statistically significant. In both the mild and SAP patients, the IL-21 levels remained near constant over the study duration.
Necrosis and Sepsis Complications in Relation to IL-21 From ELISA
Patients who developed pancreatic necrosis and systemic sepsis had higher mean levels (not statistically significant) of IL-21 on days 7 and 9 (Fig. 2) . Of the 8 patients who developed necrosis, 3 patients had moderate disease, and 5 had SAP. All 4 patients who developed septic complications were SAP patients. Interestingly, these 4 patients had elevated levels (not statistically significant) of IL-21 compared with those without sepsis (Fig. 2) .
mRNA Expression of IL-21
At day 7, IL-21 was observed to be significantly overexpressed in the plasma of patients with SAP (P = 0.002) compared with that in MAP patients (Figs. 3A) . Significantly increased levels of IL-21 were demonstrated on day 9 in both mild (P = 0.023) and severe (P = 0.002) pancreatitis compared with the control group.
In the MAP patients, IL-21 levels increased rapidly and significantly from days 7 to 9 (P < 0.0001). At day 11, IL-21 expression dropped significantly (P = 0.0024) and remained so until day 13. In SAP patients, IL-21 expression seemed to follow the same pattern as observed in MAP patients. Similarly, there was a significant increase at day 9 compared with day 7 (P = 0.026) and a decrease in expression at day 11 (P < 0.0001). In the SAP patients, the drop in IL-21 levels was not sustained as day 13 showed an increase in expression levels, although not significant.
DISCUSSION
The aim of this study was to determine the expression of IL-21 during the second hit of AP. Immune paresis, resulting from a hypoinflammatory state characterized by the compensatory antiinflammatory response syndrome, has been associated with sepsis in critically ill patients. 32, 33 Septic complications that occur in some patients with SAP may result from this immune imbalance and may be influenced by IL-21. A previous study by our group demonstrated that a T H 1/T H 2 cytokine imbalance occurs during the second hit of AP, 34 which is supported by other studies which included surgical, trauma, and burn patients. [35] [36] [37] [38] This study demonstrates that at the mRNA level IL-21 expression in plasma is increased in patients with SAP compared with MAP patients during the second hit of AP. This increase was significant only on day 9. We observed that after a drop in this mRNA expression at day 11 it appeared to increase again at day 13, although not significantly (Fig. 3) . This further indicates that IL-21 expression at mRNA level may be transient. At the protein level, IL-21 also seems to be moderately elevated in SAP patients compared with MAP (Fig. 1) . The transient nature of elevated circulating IL-21 might be due to 2 reasons: cytokines such as IL-21 are known to have short half-lives, making its production and circulation a prompt event. 39, 40 Second, IL-21 is transcriptionally regulated. For example, C-Rel − , a member of the nuclear factor κB family, regulates the expression of IL-21, 41, 42 suggesting that circulating IL-21 level may be tightly modulated.
No correlations between IL-21 mRNA and protein plasma concentrations have been previously reported in AP. In ischemic stroke patients, the IL-21 mRNA and protein concentrations in plasma were correlated consistently 43 ; however, this was in the setting of an IL-21 polymorphism that potentially up-regulated genetic expression thereof. In both systemic lupus erythematosus and rheumatoid arthritis, elevated IL-21 mRNA and plasma levels have been noted. 3 Furthermore, in trauma patients, a strong correlation between the mRNA and plasma levels of other inflammatory FIGURE 1. Enzyme-linked immunosorbent assay of IL-21 (pg/mL) on days 7, 9, 11, and 13 of disease between disease severity of AP. A, Mild/moderate AP (n = 26), SAP (n = 10), and control subjects (n = 6) (LLOQ is 4.47; ULOQ is 69.36). B, Subgroup analysis of randomly selected patients for mRNA analysis, mild AP (n = 5), SAP (n = 5), and control subjects (n = 4) (LLOQ is 5.47; ULOQ is 69.36). The error bars denote the 95% confidence limits for the estimated means. LLOQ indicates lower limit of quantification; ULOQ, upper limit of quantification.
cytokines such as IL-6 and IL-10 has been shown. 44 The mRNA and protein plasma concentrations of IL-21 in SAP are elevated compared with those in MAP patients (Figs. 1 and 3) . Although the mRNA and protein plasma levels showed increased IL-21 in SAP compared with MAP, these were, however, not significant except on day 9 (mRNA).
Interleukin-21 is a cytokine product of the T H 17 response and acts in an autocrine manner to enhance T H 17 cell differentiation. 45 Various malignancies, autoimmune diseases, viral infections, and inflammatory conditions have been linked to IL-21.
46
Immune down-regulation has been attributed to IL-21 through inhibition of regulatory T (T reg ) cells, as well as inducing the Interleukin-21 production is reliant on IL-6, as evidenced by IL-6-deficient mice demonstrating markedly reduced levels of IL-21 in vivo. 45 Regulatory T cells are immunosuppressive cells that suppress or downregulate the induction and proliferation of effector T cells. 9 Forkhead/winged helix transcription factor P3 (Foxp3) is recognized to be the most reliable marker of T reg cells. 53 Interleukin-21 effectively inhibits TGF-β-driven Foxp3, thereby limiting the differentiation of T reg cells. 11, 42 Differentiation of T cells into the T H 17 subset is dependent on TGF-β and IL-6. [8] [9] [10] Additionally, IL-21 in combination with TGF-β has been described as an alternative pathway for the differentiation of T H 17 cells, probably via the STAT3 signaling molecule. 11 Furthermore, it is perceived that IL-21 has the ability to augment the T H 17 response by means of a positive feedback loop as T H 17 cells are one of the most prominent producers of IL-21.
11,12
The loss of expression of the IL-21 or the IL21R causes a deficient T H 17 response in vitro, which further supports IL-21 involvement in T H 17 cell differentiation. 11, 42, 51, 52 Additionally, in vivo, IL-21 has been shown to significantly influence the differentiation of the T H 17 subset during the development of experimental autoimmune encephalomyelitis. 11, 42, 51, 52 Interleukin-21 is also responsible for the expression of retinoic acid receptorrelated orphan receptor-γt, which acts as the master regulator of the T H 17 phenotype. 54 In summary, these data underscore the crucial role of IL-21 in the development of T H 17 cells.
Our finding that IL-21 at both the mRNA and protein levels in plasma was elevated in SAP patients in comparison to MAP patients (Figs. 1 and 3) contrasts with a study suggesting that the T H 17 response is not active during the second hit of AP. 34 The present study assessed IL-21 expression at both mRNA and plasma level and suggests that up-regulation of IL-21 is shortlived. The transient nature of this response suggests that sampling time may be crucial in deriving conclusions concerning T H 17 responses during the second hit of AP.
Day 9 mRNA levels of IL-21 were significantly up-regulated in all SAP patients. Four patients developed septic complications, all of whom were SAP. Of these patients, the protein levels of IL-21 on day 9 were also elevated, but not significantly so (Fig. 2B) . Interleukin-21 has independently been implicated in sepsis in critically ill patients. 50 Furthermore, AP patients with pancreatic necrosis seem to have an elevated level of IL-21 expression (Fig. 2A) . This elevation was observed at day 9 corresponding to significant upregulation of IL-21 (mRNA) in both SAP and MAP patients. Pancreatic necrosis is a measure of disease severity, occurring in both moderate AP and SAP. 30 Furthermore, pancreatic necrosis is a nidus for sepsis, 19, 20, 28, 29 which significantly worsens prognosis 55, 56 in patients with AP. Indeed, 66% to 80% of late mortality that occurs in SAP is as a result of septic complication. 24, 57, 58 Importantly, our results indicate that mRNA and protein expression at day 9 (Fig. 3A) have similar trends of elevated IL-21 levels in patients with necrosis and sepsis, although protein levels (Fig. 1A) do not show these trends. This may indicate that IL-21, although transiently expressed, may play a crucial role in the complications observed in AP such as necrosis and sepsis.
This study is the first to our knowledge to quantify and compare IL-21 mRNA and protein plasma levels in AP. Although the study sample size was small, it is adequately powered to detect IL-21 level differences between the 2 study groups.
CONCLUSIONS
This study appears to be the first to report the expression of circulating IL-21 at both mRNA and protein levels during the second hit of AP. The results suggest that IL-21 may be transiently elevated in SAP compared with the mild/moderate group, and hence IL-21 may contribute to the immune imbalance that occurs in AP, thereby potentially playing a role in complications associated with AP.
